ruxolitinib (jakafi) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA
Back

Drug Pricing Summary

AUS PBS

$34.9864 - $69.9728

VA Big4

$158.2242 - $159.0205

VA FSS

$225.6322

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
ruxolitinib 10 mg (TABLET) $69.9728 AUS PBS generic
  • Jakavi (56)
  • Novartis Pharmaceuticals Australia Pty Limited
    ruxolitinib 10 mg (TABLET) $158.2242 VA Big4
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 10 mg (TABLET) $225.6322 VA FSS
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 15 mg (TABLET) $69.9728 AUS PBS generic
  • Jakavi (56)
  • Novartis Pharmaceuticals Australia Pty Limited
    ruxolitinib 15 mg (TABLET) $158.7158 VA Big4
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 15 mg (TABLET) $225.6322 VA FSS
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 20 mg (TABLET) $69.9728 AUS PBS generic
  • Jakavi (56)
  • Novartis Pharmaceuticals Australia Pty Limited
    ruxolitinib 20 mg (TABLET) $158.3142 VA Big4
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 20 mg (TABLET) $225.6322 VA FSS
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 25 mg (TABLET) $159.0205 VA Big4
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 25 mg (TABLET) $225.6322 VA FSS
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 5 mg (TABLET) $34.9864 AUS PBS generic
  • Jakavi (56)
  • Novartis Pharmaceuticals Australia Pty Limited
    ruxolitinib 5 mg (TABLET) $158.9427 VA Big4
  • JAKAFI (60)
  • Incyte Corporation
    ruxolitinib 5 mg (TABLET) $225.6322 VA FSS
  • JAKAFI (60)
  • Incyte Corporation

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue